Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838879 | 0.95 | P2RX7 (0.36) | KMT2AP2RX3ALDH1A1KDM4EPOLB | |
| SCHEMBL6267690 | 0.94 | P2RX3 (0.35) | KMT2AP2RX3ALDH1A1KDM4EPOLB | |
| SCHEMBL5838492 | 0.91 | ALDH1A1 (0.37) | KMT2AALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL5838688 | 0.90 | P2RX7 (0.39) | KMT2AALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL5957156 | 0.89 | P2RX7 (0.38) | ALDH1A1KDM4EPOLBHPGDHSD17B10 | |
| SCHEMBL5838172 | 0.88 | P2RX7 (0.36) | KMT2AALDH1A1KDM4EPOLBHPGD | |
| SCHEMBL5837231 | 0.87 | P2RX7 (0.39) | KMT2ACNR2TAAR1P2RX7 | |
| SCHEMBL5837096 | 0.86 | P2RX7 (0.39) | POLBCNR2TP53P2RX7 | |
| SCHEMBL5957066 | 0.86 | P2RX7 (0.45) | KMT2AALDH1A1CNR2HTTAVPR1B | |
| SCHEMBL5838114 | 0.85 | CNR1 (0.39) | KMT2AP2RX3CNR2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217430-A1 | Benzamide inhibitors of the P2X7 receptor | DOMBROSKI MARK A | 2006-09-28 | — | — | US | disclosed |
| US-7071223-B1 | Benzamide inhibitors of the P2X7 receptor | PFIZER, INC. (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217430-A1 | Benzamide inhibitors of the P2X7 receptor | IL1R1, P2RY1, P2RX1 | KMT2A 3644/4885P2RX3 5/4885ALDH1A1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.